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psychiatric disorders (GHQ-positive). Physician (PhGA) and patient global assess-
ments were obtained. We investigated the variables involved in the QoL through a
logistic regression analysis. RESULTS: . 195 cases were analysed. 26% were GHQ-
positive, reporting an impact on health status due to acne worse respect other
chronic diseases. Males rather than females reported a poorer QoL. A GHQ-positive
status (Skindex-29 overall: OR 2.6;95% CI 1.20-5.60,p0.05, functioning:OR 2.5;95%
CI 1.17-5.44,p0.05, symptoms:OR 3.0; 95% CI 1.36-6.53,p0.01; emotions:OR 2.55;
95% CI 1.19-5.46,p0.05) and having a severe/very severe PhGA (Skindex-29 over-
all:OR 3.4; 95% CI 1.20-10.38,p0.05) were associated with a poor QoL. Age of onset
25 was linked to being GHQ-positive (OR 2.92; 95% CI 1.2-7.1, p0.05) controlling
for gender, marital status and educational level. CONCLUSIONS: . Acne is not a
minor disease in comparison with other chronic conditions. Age of patient is ca-
pable to influence GHQ status which in turn affects QoL.
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LIMITED ROLE OF MARITAL STATUS IN THE IMPACT OF DERMATOLOGICAL
DISEASES ON QUALITY OF LIFE
Tabolli S, Pagliarello C, di Pietro C, Abeni D
IDI IRCCS, Rome, Italy
OBJECTIVES:Health status, health services utilization, andmortality differ bymar-
ital status for both sexes in most conditions, but little is known about dermatolog-
ical diseases. To evaluatewhethermarital status is associatedwith the impact that
dermatological diseases have on quality of life (QoL). METHODS: Data from two
surveys on dermatological outpatients were pooled. Marital status, sex, age, and
educational level were analysed in relation to QoL (using the scales of the Skin-
dex-29 questionnaire: emotions, symptoms, and functioning) and psychological
well-being (using the GHQ-12 questionnaire). RESULTS:We obtained data on 5471
patients (59% females, 46% married). Married patients (both males and females)
had lower mean values on the emotions scale and higher mean values in the
symptoms scale of the Skindex-29 compared to singles. Statistically significant
differences were identified only inmen, for the emotions scale and for the GHQ-12.
Females had significantly higher mean scores than males on each of the Skin-
dex-29 scales and on the GHQ-12. A multiple logistic regression model including
age, gender, and marital status, showed significant results only for gender, with
women suffering a more severe impact than men on all scales. No effect was
observed for marital status. CONCLUSIONS: Married patients had a lower disease
impact on the emotions scale even if they suffered a higher impact on the symp-
toms scale. After multiple adjustments, however, gender seems to be more rele-
vant than marital status in the evaluation of the impact of skin conditions on QoL.
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PATIENT-REPORTED OUTCOMES IN A DENTAL PRACTICE-BASED RESEARCH
NETWORK:PEARL
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OBJECTIVES: Patient-reported outcomes (PROs) such as quality of life, satisfaction
with treatment, and health status provide the patients’ viewpoint on how their
diagnosis impacts their daily lives. In dentistry, PRO use, value and logistics in the
dental practice setting remain an area for further consideration. This paper de-
scribes the PEARL PRO characteristics and discusses their implementation in a
dental PBRN setting. METHODS: The Practitioners Engaged in Applied Research
and Learning (PEARL) network has conducted 7 clinical studies in the practice-
based setting. These studies included PROs related to: oral health impact (OHIP
-14), tooth sensitivity, pain medication, and implant esthetics questionnaire. The
Food and Drug Administration issued a Regulatory Guidance on PROs which was
used as the framework for evaluation of the PRO measures. RESULTS: Of the 7
PEARL clinical studies, all used the OHIP-14, 5 studies measured tooth sensitivity
and pain medication, and one study measured patient satisfaction. A total of 6077
patients have completed the OHIP-14 scale, 2,976 patients have completed the
tooth sensitivity questionnaire, and the implant esthetics and sensitivity question-
naires have been completed by 332 patients. PROsmeasures differed in their num-
ber of items, mode of administration, and domains. We found consistent associa-
tion between the tooth sensitivity and the OHIP-14measures across PEARL studies.
CONCLUSIONS: The value of PROs in dentistry in the context of a dental practice-
based research network (PBRN) has received limited attention. Our study found
that collecting PROs is possible and that they represent an indicator of the effec-
tiveness of a dental treatment. More work is needed to inform dental practitioners
on the value of thesemeasures and to enhance themeasurement properties of the
questionnaires. The PEARL network has used several PRO measures with diverse
characteristics to adapt to the dental practice setting and to measure the dental
condition.
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ACTINIC KERATOSIS PATIENTS ARE WILLING TO PAY FOR SHORTER
TREATMENT AND LOCAL SKIN RESPONSE DURATION AND INGENOL
MEBUTATE GEL IS LIKELY TO INCREASE PATIENT LIKELIHOOD OF SUCCESSFUL
COMPLETION OF TOPICAL TREATMENT
Willis M1, Erntoft S2, Persson S1, Norlin J1, Persson U1
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Denmark
Ingenol mebutate gel is a new treatment of Actinic Keratosis (AK). The adverse
effects of current AK drug treatment involve long-lasting local skin responses
(LSRs) which may influence patient adherence negatively. OBJECTIVES: Assess
patient=s willingness-to-pay (WTP) for accessing ingenol mebutate gel instead of
imiquimod 5%, imiquimod 3.75% and diclofenac 3% in a US setting and assess
patient=s likelihood of completing a full treatment course. METHODS: A web-sur-
vey (contingent valuation design) was sent to 2000 adults, including only AK diag-
nosed subjects with self-reported AK lesions on face/scalp and/or trunk/extremi-
ties, asking them their maximum WTP to receive access to ingenol mebutate gel
instead of one of three alternative drugs. The profile was varied in three dimen-
sions; duration of treatment and treatment-related local skin responses and com-
parator price. Respondents were also asked to rank the likelihood to successfully
complete treatment course. Internal validity was checked (hypothetical drug pro-
file and income effect). RESULTS: A total of 116 subjects (105 useful) responded
(response rate 53% if AKprevalence assumed to 11%). A total of 33% stated that they
followed treatment instructions fairly well (75% of the time) or to some extent
(50%), despite experience of LSRs. Almost 90 % rated ingenol mebutate gel as the
treatment they were most likely to successfully complete; 50-63% were willing to
pay extra (mean $475-518/course) to access ingenol mebutate gel instead of the
three treatment alternatives. Subjects with experience of drug treatment stated an
incrementalWTP (mean $820/course) for accessing ingenolmebutate gel instead of
imiquimod 3.75%. Subjects currently treating the full scalp or forehead stated an
incremental WTP (mean $674 respectively $726/course) for accessing ingenol
mebutate gel instead of imiquimod 5% and diclofenac 3%. CONCLUSIONS: There is
a substantial dissatisfaction with current AK treatments and clear evidence that
patients are willing to pay for shorter treatment and LSR duration.
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DETERMINING ACCURATE DOSING OF USTEKINUMAB FROM SPECIALTY
PHARMACY DATA
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OBJECTIVES: To determine dosing patterns of ustekinumab, a biologic treatment
formoderate to severe plaque psoriasis, by analyzing prescription fill data and days
supplied from Diplomat Specialty Pharmacy (DSP). Ustekinumab is delivered as a
subcutaneous injection at weeks 0, 4, and every 12 weeks thereafter in two weight
based doses: 45mg and 90mg. METHODS: A retrospective analysis was conducted
of pharmacy fill data for patients18 years receiving2 fills of ustekinumab from
DSP between October 2009 to September 2010. Based on prescribing information
(PI), the expected time between first and second dose is 28 days / a 7-days and
the expected time between subsequent doses is 84 days/ a 14-day window. For
patients receiving 1 vial or syringe per fill, dosing was assigned based upon which
strength was initially filled. For patients receiving multiple vials or syringes per fill
(e.g. 45 mg  2), dose was based on days between fills. RESULTS: A total of 711
patients met inclusion criteria; 529 (74.4%) received one vial or syringe in the first
fill. A total of 182 patients received 2 vials or syringes, 125 (68.7%) conformed to
the expected days recommended from the PI. 57 patients (8.0%) had intervals that
fell before or after the expected time. Of the 654 (529  125) patients for whom
dosing patterns could accurately be assessed, 67.1% were dosed with 45mg.
CONCLUSIONS: Over 90% of patients had prescription fill data and intervals that
allowed for dosing patterns to be determined; the majority were dosed with 45mg.
Some patients receivedmultiple 45mg vials or syringes in one shipment, therefore
their dosing may be incorrectly interpreted as higher than their actual dose. To
appropriately analyze the dosing patterns of ustekinumab, one must account for
the number of vials or syringes supplied per fill, the strength, and the days between
fills.
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OBJECTIVES: To evaluate the relationship between weight and dose for patients
initiating ustekinumab, a biologic treatment for moderate to severe plaque psori-
asis. The recommended dosing for ustekinumab is 45mg for patients 100kg or
90mg for patients 100kg delivered as a subcutaneous injection at weeks 0, 4, and
every 12 weeks thereafter. METHODS: Patients receiving ustekinumab through
Diplomat Specialty Pharmacy (DSP) were surveyed to provide their weight. Inclu-
sion criteria were: 18 years, diagnosis of psoriasis and 2 doses of ustekinumab.
DSP provided ustekinumab shipment quantities and dates. Shipped quantities and
schedule were jointly used to estimate ambiguous doses (e.g., if two 45mg doses
were in the index shipment, the index dosewas estimated to be 90mg if the second
shipment was within 3-5 weeks; the index dose was estimated to be 45mg if the
next shipment was 12-18 weeks). RESULTS: Of 257 patients surveyed, 65% (166)
weighed100kg and 35% (91) weighed100kg. Of those100kg, 83% (138) received
a single 45mg index dose; 11% (19) received a single 90mg dose. Of those 100kg,
16% (15) received a single 45mg and 59% (54) received a single 90mg dose. Thirty-
one patients received two or more 45mg doses in the index fill (9 100kg and 22
100kg). Based on timing of the second fill for those patients, the index dose was
estimated to be 45mg and 90mg for 18 and 10 patients, respectively. Three patients
receiving two 45mgdoseswere not evaluable based on second fill date. In summary
by weight, 86% (142/166) of patients weighing 100kg are estimated to have re-
ceived an index dose of 45mg and 76% (69/91) of patients100kg likely received an
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index dose of 90mg. CONCLUSIONS: The real-world distribution of ustekinumab is
consistent with dosing recommendations in the prescribing information.
PSS28
INTRAVITREAL INJECTIONS IN AUSTRIA - RESULTS OF AN EXPERT SURVEY
AND COMPARISON WITH UTILISATION RATES FROM THE AUSTRIAN MINISTRY
OF HEALTH
Vavrovsky AD1, Kieselbach G2
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Tirol, Austria
OBJECTIVES: Intravitreal injections are an important treatment options for pa-
tients with various ophthalmologic diseases in Austria. There is a lack of data on
the real-life use of intravitreal injections in Austria. METHODS: A standardized
questionnaire on practice patternswas developed in cooperationwith theAustrian
Society of ophthalmologic surgeons. The survey was distributed among treating
ophthalmologists and results were compared to data from the Austrianministry of
health an prevalence-adjusted results from a landmark study in intravitreal
injections.RESULTS:The response rate to the surveywas 100%. Twenty-six centers
across Austria participated and reported a cumulative number of 30,124 patients
treated with intravitreal injections in 2010. The Austrianministry of health reports
30,733 intravitreal injections in 2010. Despite the fact that we have covered more
than 98% of cases in our survey, the disparities across different Austrian counties
became apparent, from the province Burgenland with only 17% of patients receiv-
ing intravitreal injections to the province of Vienna, where 44% of patients received
adequate treatment as per the CATT study. Based on a prevalence rate of 0.162%,
13,550 cases of wet AMD are expected in Austria. As there is currently no other
treatment option forwet AMD than intravitreal injections and a recent study found
the optimal dosing frequency to be seven injections per year, the number of intra-
vitreal injections should be much higher - 94,800 injections are expected if every
patient is treated according to the finding from theCATT study, namely 7 injections
per affected eye per year. As both eyes are affected in most patients, the number
should be even higher. CONCLUSIONS:More research is needed to increase infor-
mation and transparency around the epidemiology of diseases treated by intravit-
real injection and the real-life injection rates in Austria.
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OBJECTIVES: To assess real-world characteristics and severity of United States
health plan members with psoriasis receiving ustekinumab. METHODS: Medical/
pharmacy claims from the HealthCore Integrated Research Database (HIRDSM)
were analyzed. Patients included had/were:  1 ustekinumab medical/ pharmacy
claim (09/01/2009-11/30/2010); aged 18 years old at time of first ustekinumab
claim (index date); 1 psoriasis diagnosis code; and  12 months continuous en-
rollment pre-index. Patients with a medical/ pharmacy claim for another biologic
at index were excluded. Patient characteristics and severity were evaluated for the
12months pre-index, and included comorbidities, history of biologic use/psoriasis-
related topical steroids/ non-biologic systemic medications, and psoriasis-related
healthcare utilization. RESULTS: 374 patients were included (meanSD age was
4812 years; 56.4% were male). MeanSD Deyo-Charlson Comorbidity Index was
0.550.97. Dyslipidemia (46.3%) and hypertension (43.3%) were the twomost prev-
alent comorbidities prior to initiating ustekinumab. Themajority (69.5%; n260) of
patients had a history of biologic experience. Of those with pre-index biologic use,
22.3% had experience with2 biologics prior to ustekinumab. Themajority (58.0%)
of all patients had history with pre-index topical steroids; 36.4% of all patients had
history with non-biologic, systemic medications. Patients had a meanSD of
4.03.0 psoriasis-related office visits pre-index. Few had a psoriasis-related hospi-
talization (2.7%) or emergency room (ER) visit (1.9%)with ameanSDof 1.10.3 and
1.41.1 admissions or visits among patients with hospitalization or ER visit,
respectively. CONCLUSIONS: The majority of psoriasis patients receiving usteki-
numab were biologic-experienced, and nearly half had pre-existing dyslipidemia
and/or hypertension. Non-biologic, systemic medication use was evident in over a
third of all patients prior to ustekinumab. These data may be incorporated in pso-
riasis health plan programs, as there may be an opportunity to consider dyslipide-
mia and hypertension management. Furthermore, these data may be compared
with existing severity data for other psoriasis biologics.
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OBJECTIVES:Ustekinumab, a biologic used inmoderate-to-severe plaque psoriasis
(PsO), is dosed at 45mg or 90mg with health care provider (HCP) administration at
weeks 0, 4, and every 12 weeks thereafter. The objective of this study was to eval-
uate the observed dosing patterns and HCP office visits for psoriasis patients re-
ceiving ustekinumab. METHODS: The IMS LifeLink™ database was utilized to an-
alyze patients with an index pharmacy claim of ustekinumab therapy initiated
September 25, 2009 toMarch 31, 2011. Inclusion criteria: patients aged 18 years at
index,  1 PsO diagnosis code before or on index, and  360 days pre-index con-
tinuous enrollment. Ustekinumab dosing patterns included the proportion of 45mg
and 90mg doses at each of the first four fills and the time between injections.
Increases or decreases in dose between subsequent fills were assessed. Office visits
were evaluated for the 180-day post-index time period (patients required  180
days post-index continuous enrollment). RESULTS: A total of 306 PsO patients
receiving ustekinumab were evaluated. The proportion of index 45mg/90mg use
was 65%/35%. The proportion of 45mg use spanned 59%-61% across remaining fills.
Median (mean SD) interval timeswere 28 (3020), 84 (8732), and 85 (9033) days
for first to second, second to third, and third to fourth doses, respectively. Changes
in dose were observed for  7% of patients at each fill. Patients (n280) incurred a
median (mean) number of 4 (5.5) all-cause and 3 (2.5) PsO-related HCP office visits
during the first six-months after initiating therapy. CONCLUSIONS: These results
suggest that most PsO patients are initiated with a 45 mg dose. Nearly 93% of all
patients at each fill did not require dose changes over the first 4 prescriptions. The
observed interval patterns were consistent with the recommended ustekinumab
administration schedule. Additionally, patients experienced PsO-related HCP in-
teractions commensurate with the number of ustekinumab doses expected.
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ANALYSIS OF THE RELATIONSHIP BETWEENPSORIASIS SEVERITY AND
QUALITY OF LIFE, WORK PRODUCTIVITY, AND ACTIVITY IMPAIRMENT AMONG
PATIENTS WITH MODERATE TO SEVERE PSORIASIS USING STRUCTURAL
EQUATION MODELING
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Arbor, MI, USA, 3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
BACKGROUND: Plaque psoriasis is a chronic disease characterized by scaly plaques
that can itch and bleed. When psoriasis covers over 10% of the body it is classified
as moderate to severe, and can have a major impact on patient quality of life.
OBJECTIVES: The primary objective was to determine the relationship between
plaque psoriasis severity and health outcomes, work productivity, and activity
impairment among patients with moderate to severe psoriasis. METHODS: The
sample included 199 patients: 179 respondents had plaque psoriasis, 20 had plaque
and inverse psoriasis. Three psoriasis symptoms were studied (itching, pain, and
scaling). A structural equations frameworkwas used to estimate the effect of these
symptoms on patient outcomes. In the first stage, each severity variable was re-
gressed on a set of covariates to generate a predicted severity score. These pre-
dicted values were then placed in a second stage model with patient mental and
physical scores (SF-12), work productivity, and activity impairment indicators as
the dependent variables. RESULTS: Severity of itching had a negative effect on
patients’ SF-12 physical and mental component scores. The effects were margin-
ally significant (p0.06). Severity of pain was significant for physical and mental
health (p0.02). Patients were more likely to miss work because of greater itching
(OR: 2.31, CI [1.30, 4.10]), pain (OR: 1.78, CI [1.25, 2.52]), and scaling (OR: 2.15, CI [1.31,
3.52]) symptoms. These symptoms also affected productivity. More severe itching
(OR: 1.74, CI [1.03, 2.95]), scaling (OR: 1.84, CI [1.16, 2.90]), and pain symptoms (OR:
1.53, CI [1.12, 2.09]) increased the likelihood that a patient would be less productive
on the job. CONCLUSIONS: Plaque psoriasis has a significant effect on patients’
quality of life. In addition to greater mental and physical pain, patients are more
likely to miss work and have diminished productivity as the severity of symptoms
increases.
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Bacterial eye inflammation (primarily conjunctivitis) is one of the most common
cause of temporary disability in ophthalmology. Furthermore, bacterial eye inflam-
mation is one of themost common complications in the practice of ophthalmologic
surgeries and it impacts the primary operation outcome. Thus, optimization of
drug therapy and prophylaxis of bacterial eye inflammation is an actual problem of
health care system in Russia. OBJECTIVES: We provided two pharmacoeconomic
studies. In the first one a treatment of bacterial conjunctivitis with fluoroquinolo-
nes (Vigamox (moxifloxacin), Ophtakvix and Signicef (levofloxacin), Cipromed (cip-
rofloxacin) and Floxal (ofloxacin) eye-drops was considered and the second study
provided pharmacoeconomic evaluation of prophylaxis of postoperative bacterial
eye inflammation with combined eye-drops drugs of antibiotic and glucocortico-
steroid (Tobradex (tobramicinedexamethasone) andCombinil-Duo (ciprofloxacin
dexamethasone)). METHODS: Cost-efficacy analysis and cost-of-illness analysis
were used. Direct and indirect costs were considered for bacterial conjunctivitis
study and direct only costs were considered for postoperative bacterial eye inflam-
mation in pharmacoeconomic study. RESULTS: The first study has found that
Vigamox is a dominant drug to the other ones. The cost-efficacy ratio (CER) (cost of
1% of patients with successful treatment) for Vigamox it was – 1415 RUB, for Oph-
takvix – 1652 RUB, for Signicef – 1458 RUB, for Cipromed – 1674 RUB, for Floxal – 1630
RUB. Cost-efficacy analysis of postoperative bacterial eye inflammation prophy-
laxis has shown that Tobradex has dominant technology compared with to Com-
binil-Duo. CER (cost of 1% of patientswithout sign of inflammation to 14th day after
operation) for Tobradex it was – 453 RUB, for Combinil-Duo – 515 RUB.
CONCLUSIONS: Two conducted pharmacoeconomic studies show benefit of Viga-
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